HUF pancreatic cancer
Clinical research
University Hospital of Fuenlabrada.
·Fuenlabrada ·

The HUF pancreatic cancer group is currently participating in the TRIPP-FFX trial: FOLFIRINOX versus OncoSil™ in addition to FOLFIRINOX for patients with locally advanced pancreatic adenocarcinoma. This is an open-label, multicenter, randomized trial of intratumoral targeted therapy of P-32 (OncoSil™) associated with FOLFIRINOX chemotherapy compared to FOLFIRINOX alone in patients with unresectable locally advanced pancreatic adenocarcinoma. The purpose of the study is to evaluate the safety and efficacy of OncoSil™ when administered in addition to standard FOLFIRINOX chemotherapy for the treatment of locally advanced pancreatic cancer.

Main publications in pancreatic cancer:

  1. Bockorny, B., Semenisty, V., Macarulla, T. et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med 26, 878-885 (2020).
  2. Manuel Hidalgo; Francesca Sarno; Laura Medina; Roberto Pazo; Ignacio Juez; Rocío García-Carbonero; Carmen Guillén-Ponce; Jaime Feliú; Carolina Alonso; Jair Tenorio_Castano; Pablo Lapunzina. Abstract CT225: A randomized trial of integrated genomics, organoids and avatar mouse models for personalized treatment of pancreatic cancer. Cancer Res (2022) 82 (12_Supplement): CT225.
  3. Hidalgo M, Garcia-Carbonero R, Lim KH, Messersmith WA, Garrido-Laguna I, Borazanci E, Lowy AM, Medina Rodriguez L, Laheru D, Salvador-Barbero B, Malumbres M, Shields DJ, Grossman JE, Huang X, Tammaro M, Martini JF, Yu Y, Kern K, Macarulla T. A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. Cancer Res Commun. 2022 Nov 2;2(11):1326-1333. 
David Gutierrez Abad

Principal Investigator

Group members

  • David Gutiérrez Abad
  • Ignacio Juez
  • Elia Martinez
  • Francesca Sarno
  • Fernando Pereira
  • María Victoria Torres
More information

Other groups

Virology and Cellular Immunology Group – Carmen Aguilar

Our group at IrsiCaixa focuses on the development of innovative therapeutic strategies against solid tumors, with a particular emphasis on pancreatic cancer. The group integrates immunological, molecular, and translational approaches to design and evaluate cancer...

Neoantigens and Vaccines Against Cancer – Núria de la Iglesia

The Neoantigens and Cancer Vaccines group (NeoVaCan) is part of the IrsiCaixa Institute for Research on Immunopathologies, a center dedicated to the study of diseasesrelated to the immune system, ranging from viral infections, such as HIV or SARS-CoV-2, to cancer. Our...

Angiogenesis Group – Alfredo Martínez Ramírez

The Angiogenesis Group is part of the Oncology Area of the Biomedical Research Center of La Rioja (CIBIR), located in Logroño, Spain. As the name implies, the Angiogenesis Group focuses on the process of angiogenesis in relation to cancer and other relevant diseases...

See all groups